Anti-CD31 Antibodies: Expanding Applications in Oncology and Biomedical Research

The Anti-CD31 Antibody Market is expanding as pharmaceutical companies, research institutes, clinical laboratories, and academic organizations use CD31-targeting antibodies in cancer research, vascular biology, diagnostics, and therapeutic development.

According to Wise Guy Reports, the Anti-CD31 Antibody Market was valued at USD 1 billion in 2024 and is expected to grow from USD 1.1 billion in 2025 to USD 2.5 billion by 2035, registering a CAGR of 8.3%. 1396

CD31, also known as platelet endothelial cell adhesion molecule-1, is commonly associated with endothelial cells and vascular biology. Anti-CD31 antibodies are used to identify endothelial structures, study angiogenesis, analyze immune-cell interactions, and investigate tumor blood-vessel development.

Cancer therapy represents the leading application segment. Researchers are studying CD31-related pathways in tumor vascularization, metastasis, immune response, and targeted treatment. Diagnostics is another important application because anti-CD31 antibodies can assist in identifying vascular and endothelial markers in tissue samples.

Autoimmune disease research is also expanding. CD31 is involved in cell adhesion and immune regulation, creating opportunities for investigating inflammatory disorders and immune-system behavior.

Cardiovascular research uses anti-CD31 antibodies to study blood-vessel development, endothelial function, vascular injury, and cardiovascular disease mechanisms. Transplant-rejection research represents an additional application area.

Monoclonal antibodies are widely used because of their specificity and consistent performance. Recombinant antibodies are gaining interest due to their reproducibility and potential for engineering, while polyclonal antibodies remain valuable for applications that require recognition of multiple epitopes.

Research institutes and pharmaceutical companies represent major end users. Academic institutions use these antibodies in cell biology, immunology, oncology, and vascular research, while clinical laboratories apply them in immunohistochemistry, flow cytometry, and other diagnostic methods.

Mouse-derived antibodies currently hold a strong position because they are widely used in research models. Rabbit, goat, and human sources provide alternatives for different assay formats, species compatibility, and therapeutic-development requirements.

North America leads the market because of advanced biomedical research, high healthcare investment, and strong pharmaceutical development. Europe benefits from biotechnology research and academic collaborations, while Asia-Pacific is expected to grow through expanding clinical trials, research funding, and healthcare infrastructure.

The market is being shaped by advances in monoclonal antibody engineering, humanized antibodies, recombinant production, multiplex assays, flow cytometry, and artificial intelligence-assisted antibody design.

Challenges include regulatory compliance, production costs, validation requirements, batch-to-batch consistency, and competition from alternative biomarkers or technologies.

The future of the market will focus on precision oncology, immunotherapy, regenerative medicine, targeted diagnostics, and combination treatments. Strategic partnerships between antibody manufacturers, pharmaceutical companies, and research institutions will support the development of new applications.

Key companies include Cell Signaling Technology, Bio-Rad Laboratories, Abcam, Merck KGaA, Fitzgerald Industries, Thermo Fisher Scientific, R&D Systems, AntibodiesOnline, Bioss Antibodies, Novus Biologicals, and Santa Cruz Biotechnology. 1396

FAQs

Q1. What are anti-CD31 antibodies?
They are antibodies designed to recognize the CD31 marker, which is associated with endothelial cells and vascular biology.

Q2. Where are they used?
They are used in cancer research, diagnostics, cardiovascular studies, autoimmune research, transplant studies, and immunology.

Q3. Which application leads the market?
Cancer therapy and oncology research represent the leading application area.

Q4. What antibody types are available?
The market includes recombinant, monoclonal, and polyclonal anti-CD31 antibodies.

Q5. What is the market forecast?
The market is expected to reach USD 2.5 billion by 2035 at a CAGR of 8.3%. 1396

Tags: Anti-CD31 Antibody Market, CD31 antibodies, monoclonal antibodies, cancer research, endothelial markers, immunohistochemistry, flow cytometry, biomedical research